[
    [
        {
            "time": "2021-01-21",
            "original_text": "药明康德：超预期，看好2021年高增长延续、天花板提升",
            "features": {
                "keywords": [
                    "药明康德",
                    "超预期",
                    "高增长",
                    "天花板提升"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德：超预期，看好2021年高增长延续、天花板提升",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-21",
            "original_text": "盘后公告集锦|东方日升与福莱特签订近90亿元光伏玻璃重大销售合同 药明康德、江铃汽车年度净利大幅预增",
            "features": {
                "keywords": [
                    "药明康德",
                    "净利大幅预增",
                    "光伏玻璃",
                    "销售合同"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物",
                    "新能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "盘后公告集锦|东方日升与福莱特签订近90亿元光伏玻璃重大销售合同 药明康德、江铃汽车年度净利大幅预增",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-21",
            "original_text": "【盈喜】药明康德(02359-HK)料年度盈利50%到60%",
            "features": {
                "keywords": [
                    "药明康德",
                    "年度盈利",
                    "50%-60%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【盈喜】药明康德(02359-HK)料年度盈利50%到60%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-01-21",
            "original_text": "药明康德(603259.SH)2020年度净利润预增50%-60%",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020年度",
                    "净利润预增",
                    "50%-60%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(603259.SH)2020年度净利润预增50%-60%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-01-21",
            "original_text": "药明康德：预计2020年净利润同比增长50%至60%",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020年",
                    "净利润",
                    "同比增长",
                    "50%-60%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德：预计2020年净利润同比增长50%至60%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-01-21",
            "original_text": "天演药业赴美IPO：药明康德持股10.8%，产品尚未上市亏损持续扩大 亏损",
            "features": {
                "keywords": [
                    "天演药业",
                    "赴美IPO",
                    "药明康德",
                    "持股10.8%",
                    "亏损持续扩大"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "天演药业赴美IPO：药明康德持股10.8%，产品尚未上市亏损持续扩大 亏损",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-21",
            "original_text": "医药生物行业周报：国家医保局发布“两定办法”",
            "features": {
                "keywords": [
                    "医药生物",
                    "国家医保局",
                    "两定办法"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业周报：国家医保局发布“两定办法”",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-01-21",
            "original_text": "医药生物行业：高景气CXO行业或持续高增长 多个CXO公司发布2020业绩预告 数据超预期",
            "features": {
                "keywords": [
                    "医药生物",
                    "CXO行业",
                    "高增长",
                    "业绩预告",
                    "数据超预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：高景气CXO行业或持续高增长 多个CXO公司发布2020业绩预告 数据超预期",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]